Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03700320 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 744
- Enrollment target
NCT03700320 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 744 participants.
The verdict
NCT03700320, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 744 participants
- Enrollment target
Study Summary
This study will evaluate safety and tolerability of treatment with atogepant for the prevention of episodic migraine over the course of one year.
Interventions
- DRUG Atogepant
- DRUG Standard of Care (SOC) Migraine Preventive Medication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 744 participants |
| Start Date | 2018-10-08 |
| Est. Completion | 2020-05-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03700320
The ClinicalTrials.gov registry entry for NCT03700320 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 744 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atogepant is the first listed.
NCT03700320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03700320 about?
NCT03700320 is a clinical study titled "Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine". This study will evaluate safety and tolerability of treatment with atogepant for the prevention of episodic migraine over the course of one year.
What is the current status of trial NCT03700320?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 744 participants. The study started on 2018-10-08. Estimated completion is 2020-05-21.
What interventions are being tested in trial NCT03700320?
The interventions under investigation include: Atogepant (DRUG), Standard of Care (SOC) Migraine Preventive Medication (DRUG).
Who is sponsoring clinical trial NCT03700320?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.